Zepbound KwikPen: 4 Weekly Doses in One Pen

Summary: The Zepbound KwikPen holds four weekly tirzepatide doses in one device. What the FDA label says about strengths, priming, storage, disposal and cost.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The Zepbound KwikPen is a disposable, multi-dose, single-patient-use prefilled pen that holds four fixed weekly doses of tirzepatide in one device. Instead of four separate single-dose pens for a month of treatment, you get one pen, dial and prime it each week, and throw it away after the fourth dose. Eli Lilly announced FDA approval of the KwikPen presentation and its availability on February 23, 2026.

It is the same drug at the same weekly dose. What changes is the device, the injection volume, the formulation's preservatives, and a handling step the single-dose pen never asked you to do.

What the Zepbound KwikPen actually is

The KwikPen is one of four Zepbound presentations now listed in the FDA prescribing information: prefilled single-dose pens, single-dose vials, multi-dose vials, and single-patient-use KwikPens. The multi-dose vial and the KwikPen each contain four doses.

Each KwikPen holds 2.4 mL of solution and delivers four doses of 0.6 mL. The label notes the pen contains a small amount of extra volume beyond that, specifically to allow for device priming.

The device has a dose knob, a dose window, a cartridge holder with a red inner seal, and a pen cap. If that sounds like an insulin pen, that is the family it comes from. The same four-dose KwikPen presentation now appears in the Mounjaro label as well.

Strengths and how much drug is in the pen

Six strengths are approved, matching the six single-dose strengths:

Each pen is a single strength. It is not a device you dial up from 2.5 mg to 5 mg. When your prescriber moves you to the next step on the Zepbound dosing schedule, you get a new pen at the new strength. Dose selection and escalation timing are a prescriber's decision, not something the device lets you improvise.

KwikPen versus the single-dose Zepbound pen

Three differences in the label are worth knowing before you switch.

Injection volume. The single-dose pen and single-dose vial deliver each dose in 0.5 mL. The KwikPen and multi-dose vial deliver the same milligram dose in 0.6 mL. Same drug, same dose, slightly more liquid going in. If you have been tracking millilitres, see how many mL is 2.5 mg of tirzepatide for why the number moves without the dose changing.

Preservatives. This is the part most write-ups skip. The single-dose pen and single-dose vial list only sodium chloride, sodium phosphate dibasic heptahydrate and water for injection as excipients. Because the KwikPen and multi-dose vial are punctured repeatedly, each dose also contains benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg) and sodium phosphate dibasic heptahydrate (0.8 mg). If you have a known sensitivity to benzyl alcohol or phenol, that is a real conversation to have with your prescriber, not a footnote.

Pen needles. The KwikPen Instructions for Use lists a KwikPen-compatible pen needle under supplies needed, with the explicit note that needles are not included. You attach a fresh one for every injection and dispose of it in a sharps container immediately afterwards. The label also warns not to store the pen with a needle attached, because that invites leaking, blocked needles and air entering the cartridge.

Lilly's prescribing information makes the general point directly: patients and caregivers should be told which presentation they are receiving and trained for that specific device, and if the prescribed presentation changes, they should be retrained and consult the Instructions for Use for the new one. The techniques are not interchangeable.

Priming: the step that trips people up

The single most common KwikPen mistake is treating it like a device that primes once. It does not.

The Instructions for Use says to prime before each weekly injection. The described sequence is: turn the dose knob until you hear two clicks and the extended line shows in the dose window, hold the pen needle-up and tap the cartridge holder to bring air bubbles to the top, then push the dose knob in until it stops and hold for a slow count of five. A small drop of medicine at the needle tip means the pen is primed.

If nothing appears, the label allows repeating those steps up to two more times, then changing the pen needle and trying once more, then calling Lilly at 1-800-545-5979 rather than injecting a pen that has not primed.

For the injection itself, the label says to turn the dose knob all the way until it stops and confirm the dose icon is in the window, and explicitly says not to count clicks to select a dose. After pushing the knob in, hold for five seconds before withdrawing. Injection sites listed are the thigh or the abdomen at least two inches from the navel, or the back of the upper arm if someone else is injecting, rotating the site each week. General technique carries over from how to inject tirzepatide, but the priming step is specific to this device.

Storage and when to throw the pen away

Storage rules differ from the single-dose pen, and the difference matters because a KwikPen sits around for a month.

Unopened KwikPens go in the refrigerator at 2 to 8 °C (36 to 46 °F) and can be used until the expiration date on the label if they stay refrigerated. If an unopened pen is kept at room temperature, up to 30 °C (86 °F), it must be discarded after 30 days.

Once you have used it, the pen can live in the refrigerator in its original carton or at room temperature up to 30 °C. The discard rule is whichever of these comes first: 30 total days at room temperature, 30 days after first use, or four weekly doses given. Throw it away even if medicine is visibly left in it.

The pen enforces the four-dose limit mechanically. The Instructions for Use says the pen will prevent you from dialling a full dose after the fourth weekly dose, and that if the knob will not turn to a full dose you should discard the pen rather than inject the remainder. It also says not to transfer Zepbound from the pen into a syringe.

Do not freeze it, and discard any pen that has been frozen. For the wider picture on cold chain, see does Zepbound need to be refrigerated.

What the KwikPen costs

Lilly launched the KwikPen through LillyDirect for self-pay patients on February 23, 2026, at a starting price of $299 per month for the 2.5 mg dose, and later made the same self-pay pricing available at major pharmacies through a KwikPen self-pay savings card.

On Lilly's own coverage and savings page, KwikPen self-pay pricing for a one-month prescription is listed as $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg, 10 mg, 12.5 mg and 15 mg. Prices without that savings program are listed higher at the upper strengths. Patients with commercial insurance that covers Zepbound may pay as little as $25 with the Lilly Savings Card, subject to eligibility.

These figures change, and eligibility rules are the fine print that decides what you actually pay. Verify current pricing on Lilly's page before budgeting. Broader options are covered in Zepbound cost without insurance.

Who should not self-inject with a KwikPen

The prescribing information carries one explicit carve-out: the Zepbound KwikPen is not recommended for self-administration by people who are visually impaired. The Instructions for Use repeats it, saying people who are blind or have vision problems should not use the pen without help from someone trained to use it. The device relies on reading an icon in a small dose window to confirm a full dose was delivered, which is why.

The label also adds a warning section that does not exist for single-dose presentations: never share a KwikPen between patients, even if the pen needle is changed, because of bloodborne pathogen transmission risk. That is standard for any multi-dose pen and is why it is labelled single-patient-use.

Everything else about tirzepatide is unchanged by the device. The contraindications, the boxed warning about thyroid C-cell tumours, and the gastrointestinal side effect profile all still apply. See tirzepatide side effects for that side of the picture.

FAQ

Is the Zepbound KwikPen the same medicine as the single-dose pen? Yes, the active drug and the weekly milligram dose are identical. The delivery volume is 0.6 mL instead of 0.5 mL, and the KwikPen formulation contains preservatives (benzyl alcohol, phenol, glycerin) that the single-dose presentations do not.

How many doses are in one Zepbound KwikPen? Four fixed doses, one per week, so one pen covers roughly a month. After the fourth dose the pen locks out further full doses and should be discarded with any remaining medicine still inside.

Do I have to prime the KwikPen every time? The Instructions for Use says to prime before each weekly injection. This is different from devices that prime once at first use. Skipping it risks an incomplete dose because air in the cartridge has not been cleared.

Are pen needles included with the Zepbound KwikPen? No. The Instructions for Use lists KwikPen-compatible pen needles as a supply you need and states they are not included. You use a new needle for each injection and remove it before storing the pen.

Is there a Mounjaro KwikPen too? Yes. The Mounjaro US prescribing information lists the same single-patient-use KwikPen presentation with four weekly doses across the same six strengths. Mounjaro is the type 2 diabetes brand of tirzepatide; the differences are covered in Mounjaro vs Zepbound.

Can I keep a KwikPen out of the fridge for the whole month? The label permits an in-use pen to be stored at room temperature up to 30 °C, but the total room-temperature clock is 30 days and the pen must be discarded at 30 days after first use regardless. Unopened pens kept at room temperature must also be discarded after 30 days rather than held to the printed expiry.

This article describes what FDA-approved labelling and manufacturer materials report about the Zepbound KwikPen device. It is not medical advice. Dose selection, escalation and whether a multi-dose pen is appropriate for you are decisions for your prescriber.